Contact Us
Drug Search Results
More Filters [+]

Tetracycline

Alternative Names: tetracycline, tetracyclin, tetracyclines, mrc-375, mrc 375, mrc375, tetraciclina, sumycin, achromycin v, bristacycline, cyclopar, tetrex, retet, tetrachel, robitet, panmycin, actisite, topicycline, tetramed, pylera, achromycin, tetracyn, helidac, helidac therapy
Latest Update: 2024-12-11
Latest Update Note: Clinical Trial Update

Product Description

Tetracyclines (tetracycline, doxycycline, minocycline, tigecycline) are a class of medication used to manage and treat various bacterial infections. Tetracyclines classify as protein synthesis inhibitor antibiotics and are considered to be broad-spectrum. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31751095/)

Mechanisms of Action: Protein Synthesis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Topical

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Jordan | Korea | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tetracycline

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

12/09/2024

News Article

 Senseonics Holdings, Inc. Provides Update on Eversense 365 Launch

11/29/2024

News Article

 Antibiotics and Antimycotics Market Size to Hit $91.54 Billion, Globally at 5.2% CAGR by 2031 - Exclusive Report by The Insight Partners

11/28/2024

News Article

 Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China's National Reimbursement Drug List

11/14/2024

News Article

 Paratek Pharmaceuticals Announces Completion of U.S. Onshoring Program, Making NUZYRA® (omadacycline) the Only Novel Antibiotic with Domestic Supply and Manufacturing Capabilities

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions